IC
Ikarian Capital Portfolio holdings
AUM
$302M
This Quarter Return
-1.15%
1 Year Return
+65.21%
3 Year Return
+441.33%
5 Year Return
+548.26%
10 Year Return
–
AUM
$320M
AUM Growth
-$47.2M
(-13%)
Cap. Flow
+$17.5M
Cap. Flow
% of AUM
5.47%
Top 10 Holdings %
Top 10 Hldgs %
52.44%
Holding
116
New
16
Increased
13
Reduced
23
Closed
13
Top Buys
| 1 |
Enliven Therapeutics
ELVN
|
$13.7M |
| 2 |
Amgen
AMGN
|
$12M |
| 3 |
Sarepta Therapeutics
SRPT
|
$8.11M |
| 4 |
Viking Therapeutics
VKTX
|
$7.33M |
| 5 |
Cartesian Therapeutics
RNAC
|
$6.55M |
Top Sells
| 1 |
Corbus Pharmaceuticals
CRBP
|
$11.3M |
| 2 |
ALPN
Alpine Immune Sciences, Inc. Common Stock
ALPN
|
$10.4M |
| 3 |
Praxis Precision Medicines
PRAX
|
$10.3M |
| 4 |
Alnylam Pharmaceuticals
ALNY
|
$7.7M |
| 5 |
Annexon
ANNX
|
$5.02M |
Sector Composition
| 1 | Healthcare | 99.74% |
| 2 | Real Estate | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
SLN
26
Silence Therapeutics
SLN
$237M
| $3.29M | 0.57% |
+506,665
| New | +$3.29M |
|
27
Inhibrx
INBX
$403M
| $3.26M | 0.57% |
+230,000
| New | +$3.26M |
|
28
Abeona Therapeutics
ABEO
$356M
| $3.26M | 0.57% |
768,593
-120,000
| -14% | -$509K |
|
29
Insmed
INSM
$30.3B
| $3.2M | 0.56% |
47,835
-3,500
| -7% | -$235K |
|
30
Terns Pharmaceuticals
TERN
$651M
| $3.12M | 0.54% |
458,497
+370,000
| +418% | +$2.52M |
|
|
VRNA
31
Verona Pharma
VRNA
$9.18B
| $2.91M | 0.51% |
201,116
-174,194
| -46% | -$2.52M |
|
32
Wave Life Sciences
WVE
$1.27B
| $2.87M | 0.5% |
575,088
-15,000
| -3% | -$74.9K |
|
33
Jasper Therapeutics
JSPR
$44.2M
| $2.39M | 0.42% |
105,175
| – | – |
|
34
Larimar Therapeutics
LRMR
$337M
| $2.35M | 0.41% |
323,528
-115,000
| -26% | -$834K |
|
35
Arcus Biosciences
RCUS
$1.24B
| $2.21M | 0.38% |
+145,000
| New | +$2.21M |
|
36
Q32 Bio
QTTB
$20.9M
| $1.96M | 0.34% |
109,094
+86,759
| +388% | +$1.56M |
|
|
ELEV
37
DELISTED
Elevation Oncology
ELEV
| $1.86M | 0.32% |
690,089
+542,000
| +366% | +$1.46M |
|
|
38
Annexon
ANNX
$225M
| $1.86M | 0.32% |
380,000
-1,025,000
| -73% | -$5.02M |
|
|
CMPS
39
Compass Pathways
CMPS
$452M
| $1.83M | 0.32% |
+302,908
| New | +$1.83M |
|
40
Nektar Therapeutics
NKTR
$543M
| $1.63M | 0.28% |
+87,494
| New | +$1.63M |
|
41
Scholar Rock
SRRK
$3.3B
| $1.53M | 0.27% |
183,701
-108,000
| -37% | -$900K |
|
42
Sagimet Biosciences
SGMT
$239M
| $1.41M | 0.25% |
412,565
| – | – |
|
43
Tourmaline Bio
TRML
$645M
| $1.4M | 0.24% |
108,483
| – | – |
|
44
iBio
IBIO
$16.9M
| $1.27M | 0.22% |
600,000
| – | – |
|
45
InflaRx
IFRX
$117M
| $1.23M | 0.21% |
704,987
| – | – |
|
|
ACHL
46
DELISTED
Achilles Therapeutics plc American Depositary Shares
ACHL
| $1.18M | 0.2% |
1,443,181
| – | – |
|
47
MindMed
MNMD
$689M
| $1.17M | 0.2% |
162,481
-135,000
| -45% | -$973K |
|
|
ITOS
48
DELISTED
iTeos Therapeutics
ITOS
| $1.17M | 0.2% |
78,574
-22,751
| -22% | -$338K |
|
49
Kodiak Sciences
KOD
$453M
| $1.12M | 0.2% |
476,586
| – | – |
|
50
Roivant Sciences
ROIV
$8.6B
| $1.06M | 0.19% |
100,609
| – | – |
|